Target Corp. (NYSE: TGT) has long been a staple for retail stores within the United States. Now CVS Health Corp. (NYSE: CVS) is getting a piece of the action in its most recent acquisition.
Both companies announced a definitive agreement in which CVS will acquire Target’s pharmacy and clinic businesses for roughly $1.9 billion. Specifically, CVS will acquire Target’s 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy.
Barclays served as a financial advisor for CVS while Goldman Sachs was the financial advisor for Target.
Going forward, CVS will operate pharmacies within all new Target stores that offer pharmacy services. Target’s nearly 80 clinic locations will be rebranded as MinuteClinic, and CVS will open up to 20 additional clinics in Target stores within three years of the close of the transaction. The new clinics will be part of CVS/MinuteClinic’s plan to operate 1,500 clinics by 2017.
If this transaction was only valued at the pharmacy level, CVS would be paying about $1.14 million per pharmacy, which is relatively cheap. Target looks to benefit from this too, as this is a significant cut to its overhead.
CVS expects this transaction to generate significant sales and prescription volumes on closing, and over the long term to generate a significant operating profit. This transaction will be financed through additional debt. According to the company:
In combination with CVS Health’s planned acquisition of Omnicare, this transaction will increase the company’s Adjusted Debt to EBITDA leverage ratio to approximately 3.2x. In support of reaching its leverage target of 2.7x, CVS Health is reducing its share repurchase guidance for 2015 by $1 billion, from $6 billion to $5 billion. This reduction in share repurchases reduces the company’s 2015 Adjusted Earnings Per Share guidance by approximately one cent per share and will lower 2016 Adjusted Earnings Per Share by approximately 4 cents per share.
Both companies noted that the current timing of the transaction is uncertain, but it is expected to close within the year.
Shares of Target closed Friday down 0.8% at $79.47, in a 52-week trading range of $57.06 to $83.98. In premarket trading Monday, shares were up about 0.3% at $79.70. The stock has a consensus analyst price target of $81.32.
CVS shares closed Friday down 0.4% at $102.22. In premarket trading Monday, shares were up 0.7% at $102.92. The consensus price target is $115.40 and the 52-week range is $74.64 to $105.46.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.